Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2016

View Archived Issues

AZD-7325, increases test stimulus intensity at 2-h post-dose in a phase I crossover study

Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis

DWN-10899, a novel Nav1.7 blocker significantly blocks neuropathic pain in mouse model

Sanford-Burnham Medical Research Institute patents APJ agonists

Janssen Pharmaceutica discloses TARPgamma8 modulators

Eli Lilly and Company describes BACE1 inhibitors

Chinese researchers develop antiviral agents

Sanford-Burnham Medical Research Institute presents EphA4 inhibitors

Gilead Sciences returns GS-4774 rights to GlobeImmune

Janssen submits application to FDA seeking approval of guselkumab

Agilis Biotherapeutics' AGIL-AADC wins FDA rare pediatric disease designation

FDA approves Intrarosa to treat dyspareunia in postmenopausal women

Endo's CCH significantly improves cellulite in phase II study

Resverlogix's apabetalone shows favorable PK profile in severe renal impairment

Cellectar Biosciences reports advances in Pierre Fabre research collaboration

ProMetic Life Sciences's PBI-4050 shows efficacy in phase II study in IPF

Celgene acquires marizomib assets from Triphase Accelerator

Novan reports promising preclinical data on SB-414 for psoriasis

Immune Pharmaceuticals secures new financing

Namodenoson approved as generic name for CF-102

Launch of International PSC Genome Project for primary sclerosing cholangitis

FDA awards fast track designation to Eisai's BACE inhibitor for Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...